BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Treskova M, Scholz SM, Kuhlmann A. Cost Effectiveness of Elderly Pneumococcal Vaccination in Presence of Higher-Valent Pneumococcal Conjugate Childhood Vaccination: Systematic Literature Review with Focus on Methods and Assumptions. PharmacoEconomics 2019;37:1093-127. [DOI: 10.1007/s40273-019-00805-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Feemster KA, Kim Y, Abe M, Johnson K, Sasaki S. Response to Igarashi, et al, cost-effectiveness analysis for PCV13 in adults 60 years and over with underlying medical conditions which put them at an elevated risk of pneumococcal disease in Japan. Expert Rev Vaccines 2022;:1-2. [PMID: 35172667 DOI: 10.1080/14760584.2022.2036127] [Reference Citation Analysis]
2 Deb A, Guggisberg P, Mutschler T, Owusu-Edusei K, Bencina G, Johnson KD, Ignacio T, Mathijssen D, Qendri V. Cost-effectiveness of the 15-valent pneumococcal conjugate vaccine for high-risk adults in Switzerland. Expert Rev Vaccines 2022. [PMID: 35220875 DOI: 10.1080/14760584.2022.2046468] [Reference Citation Analysis]
3 Vila-corcoles A, Hospital I, Ochoa-gondar O, Satue E, de Diego C, Vila-rovira A, Gómez-bertomeu F, Raga X, Aragón M. Clinical effectiveness of 13-valent and 23-valent pneumococcal vaccination in middle-aged and older adults: The EPIVAC cohort study, 2015–2016. Vaccine 2020;38:1170-80. [DOI: 10.1016/j.vaccine.2019.11.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Dawson R, Buchwald U, Johnson KD, Spowart L. Response to Vyse et al., "A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK". Expert Rev Vaccines 2022. [PMID: 35285368 DOI: 10.1080/14760584.2022.2047023] [Reference Citation Analysis]
5 Feldman C, Dlamini SK, Madhi SA, Meiring S, von Gottberg A, de Beer JC, de Necker M, Stander MP. The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults. PLoS One 2020;15:e0227945. [PMID: 31995597 DOI: 10.1371/journal.pone.0227945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Sevilla JP, Stawasz A, Burnes D, Agarwal A, Hacibedel B, Helvacioglu K, Sato R, Bloom DE. Indirect costs of adult pneumococcal disease and the productivity-based rate of return to the 13-valent pneumococcal conjugate vaccine for adults in Turkey. Hum Vaccin Immunother 2020;16:1923-36. [PMID: 31995443 DOI: 10.1080/21645515.2019.1708668] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
7 Vyse A, Campling J, Czudek C, Ellsbury G, Mendes D, Reinert RR, Slack M. A review of current data to support decision making for introduction of next generation higher valency pneumococcal conjugate vaccination of immunocompetent older adults in the UK. Expert Rev Vaccines 2021;20:1311-25. [PMID: 34550850 DOI: 10.1080/14760584.2021.1984888] [Reference Citation Analysis]
8 Shao Y, Stoecker C. Cost-effectiveness of pneumococcal vaccines among adults over 50 years old in low- and middle-income countries: a systematic review. Expert Rev Vaccines 2020;19:1141-51. [PMID: 33428494 DOI: 10.1080/14760584.2020.1874929] [Reference Citation Analysis]